Major Shift in the Oral TYK2 Inhibitor Landscape for Psoriasis! June 12,Takeda PharmaceuticalOfficial Announcement of Core Pipeline Drugszasocitinib（TAK-279）Breakthrough Phase 3 Clinical Results: In a Head-to-Head Controlled Trial in Moderate-to-Severe Plaque Psoriasis, This Next-Generation Highly Selective TYK2 InhibitorCompletely Outperforming BMS(Bristol-Myers Squibb)Flagship DrugSotyktu(Deucravacitinib), with therapeutic efficacy far surpassing competitors, formally realizing the investment value of the $6 billion blockbuster deal.

Source: Corporate Website

ZasocitinibBy biotechnology companyNimbus TherapeuticsIndependently developed, it is aNew-Generation Highly Selective Oral TYK2 Inhibitor, and it is also a highly competitive innovative candidate drug in the current field of psoriasis treatment.Mosheng Pharmaceutical data shows，The drug first applied for clinical trials in China in October 2023, received approval for clinical trials in January 2024, and entered Phase I clinical trials in April. Its indications include psoriatic arthritis, ulcerative colitis, Crohn's disease, psoriasis, and pustular psoriasis; on May 29, 2024, a Phase III clinical trial targeting plaque psoriasis was also initiated.

Screenshot source: PharmCube Global Drug R&D Database (Click for moreMini ProgramView)

Compared with traditional JAK inhibitors,zasocitinibPossesses ultimate target selectivity: Its inhibitory selectivity for the TYK2 target is superior to that of other JAK family enzymesMore than 1 million times higher, it can precisely target core pathogenic immune pathways in psoriasis, such as IL-23, achieving sustained homeostatic inhibition over 24 hours, while completely avoiding off-target side effects associated with JAK1/2/3 inhibition. This mechanism balances potent efficacy with safety, representing a modified innovative drug with significant differentiated advantages.

With impressive Phase II clinical data, this drug demonstrated its potential to surpass existing drugs in the same class at an early stage and successfully attracted Takeda Pharmaceutical. In December 2022, Takeda initiated a major strategic move by$4 billion upfront payment + up to $2 billion in sales milestone paymentstotal cost(Totaling $6 billion), acquired 100% of Nimbus Lakshmi, Inc., which is in the Phase III clinical trial preparation stagezasocitinibAcquire the entire portfolio.

At that time, the industry widely believed that the core objective of Takeda’s sky-high-priced deal was to develop a “best-in-class” drug capable of directly challenging BMS’s Sotyktu.（Best-in-class）"Oral therapy for psoriasis. The release of the Phase 3 head-to-head data perfectly confirms the initial predictions."

It is worth noting that,Nimbus Therapeutics has repeatedly set records for licensing deals in the pharmaceutical industry, having previously licensed multiple core-target drugs to giants such as Gilead and Genentech. This collaboration with Takeda further extends its streak of blockbuster transactions.

The newly releasedLATITUDE Atlas（TAK-279-PsO-3004）The study is a multicenter, randomized, double-blind, active-controlled Phase III clinical trial. It is also one of the few positive head-to-head comparative studies in the psoriasis TYK2 inhibitor landscape, carrying substantial scientific and clinical significance.

Screenshot source: PharmCube Global Drug R&D Database (Click for moreMini ProgramView)

The trial enrolled a total of606 Patients with Moderate-to-Severe Plaque Psoriasis, respectively using the standard dosing regimen:zasocitinib30 mg once daily versus Sotyktu 6 mg once daily treatment: significant difference in core efficacy data – primary endpoint(Week 16 PASI 100 Complete Skin Clearance Rate)：zasocitinibOver 35% of patients in the group achieved complete clearance of skin lesions,Efficacy is more than 2.5 times that of BMS Sotyktu; among whichzasocitinibThe maximum skin lesion clearance rate can reach 33.4%, while Sotyktu is only at 14%. The difference in efficacy is visually apparent, clearly demonstrating a generational gap.

Meanwhile,zasocitinibInAll key secondary endpoints achieved statistically significant superiority, encompassing core endpoints such as the Week 16 PASI 90 response rate (near-complete clearance of skin lesions) and an sPGA (static Physician’s Global Assessment) score of 0 (complete resolution of skin lesions), demonstrating comprehensive superiority over existing benchmark therapies.

Beyond its overwhelmingly superior core therapeutic efficacy,zasocitinibIt also demonstrates impressive performance in terms of onset speed and medication safety, combining clinical practicality with long-term therapeutic value. In terms of onset, the drug possessesFaster Onset of Actionits core advantages, significant improvement in skin lesions can be achieved by week 8 of treatment, rapidly alleviating patient symptoms and effectively addressing the clinical pain points of traditional oral psoriasis medications, which are characterized by slow onset of action and delayed symptom improvement, thereby greatly enhancing patient treatment adherence and satisfaction with medical care. In terms of safety, the Phase III clinical data confirm that,zasocitinibThe overall safety and tolerability profile is excellent, with no new safety signals identified. Leveraging its exceptional TYK2 target selectivity—over a million-fold higher—it effectively avoids the off-target risks associated with traditional JAK inhibitors, thereby establishing a solid safety foundation for long-term continuous treatment in patients.

Zasocitinib: Global and China Top 10 Data

Screenshot source: Minseng Pharmaceutical Global Drug R&D Database (click for moreMini ProgramView)

The comprehensive victory in this head-to-head Phase III clinical trial has thoroughly reshaped the global competitive landscape for TYK2-targeted therapies in psoriasis. Previously, BMS’s Sotyktu, as the first highly selective TYK2 inhibitor, had long maintained its position as the benchmark for innovative oral treatments in psoriasis and remained a core blockbuster drug in the global field of inflammatory and immune diseases.zasocitinibThe outstanding data not only validates Nimbus’s differentiated, high-precision target discovery and development capabilities, but also formally disrupts the existing market landscape, signaling the emergence of a formidable competitor in the industry. Takeda’s strategic investment, valued at up to $6 billion, has now fully realized its value, leveragingSuperior Efficacy, Faster Onset, Better Safety ProfileThe triple core advantages,zasocitinibPoised to disrupt the current oral treatment landscape for psoriasis, it is set to become the new preferred oral therapy for patients with moderate-to-severe plaque psoriasis, bringing a groundbreaking advancement to the global treatment of immune-mediated inflammatory diseases.

END

This article is an original work. Please leave a message to obtain authorization for reposting.

Contact Us to Experience More Professional Services from MoShang Pharma
Meeting Cooperation	Media Collaboration	Database Consultation	Data Customization	Report Customization

ClickReadRead the original textApply for a free trial of the Moshang Pharmaceutical Enterprise Edition!